Immuneering Corp (IMRX)
1.47
-0.07
(-4.55%)
USD |
NASDAQ |
May 17, 16:00
1.47
0.00 (0.00%)
After-Hours: 20:00
Immuneering Enterprise Value: -27.69M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | -27.69M |
| May 16, 2024 | -25.61M |
| May 15, 2024 | -24.72M |
| May 14, 2024 | -23.83M |
| May 13, 2024 | -24.13M |
| May 10, 2024 | -28.28M |
| May 09, 2024 | -25.02M |
| May 08, 2024 | -22.94M |
| May 07, 2024 | -25.02M |
| May 06, 2024 | -22.35M |
| May 03, 2024 | -22.65M |
| May 02, 2024 | -25.02M |
| May 01, 2024 | -25.91M |
| April 30, 2024 | -29.17M |
| April 29, 2024 | -27.39M |
| April 26, 2024 | -27.69M |
| April 25, 2024 | -28.87M |
| April 24, 2024 | -26.80M |
| April 23, 2024 | -22.94M |
| April 22, 2024 | -20.27M |
| April 19, 2024 | -17.90M |
| April 18, 2024 | -18.79M |
| April 17, 2024 | -16.12M |
| April 16, 2024 | -16.72M |
| April 15, 2024 | -14.49M |
| Date | Value |
|---|---|
| April 12, 2024 | -9.006M |
| April 11, 2024 | -9.599M |
| April 10, 2024 | -11.68M |
| April 09, 2024 | -6.337M |
| April 08, 2024 | -8.413M |
| April 05, 2024 | -6.337M |
| April 04, 2024 | -1.593M |
| April 03, 2024 | -0.1102M |
| April 02, 2024 | 2.855M |
| April 01, 2024 | 10.27M |
| March 28, 2024 | -1.037M |
| March 27, 2024 | -14.51M |
| March 26, 2024 | -15.68M |
| March 25, 2024 | -11.58M |
| March 22, 2024 | -10.99M |
| March 21, 2024 | -5.722M |
| March 20, 2024 | -4.258M |
| March 19, 2024 | -10.41M |
| March 18, 2024 | -10.70M |
| March 15, 2024 | -29.73M |
| March 14, 2024 | -0.7441M |
| March 13, 2024 | 86.52M |
| March 12, 2024 | 85.79M |
| March 11, 2024 | 88.13M |
| March 08, 2024 | 106.43M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-35.13M
Minimum
May 25 2022
801.56M
Maximum
Sep 27 2021
159.62M
Average
106.69M
Median
Enterprise Value Benchmarks
| Geron Corp | 1.900B |
| SELLAS Life Sciences Group Inc | 65.91M |
| Elicio Therapeutics Inc | 89.83M |
| ADMA Biologics Inc | 2.220B |
| Outlook Therapeutics Inc | 179.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.31M |
| Total Expenses (Quarterly) | 15.33M |
| EPS Diluted (Quarterly) | -0.49 |
| Earnings Yield | -127.2% |
| Normalized Earnings Yield | -130.61 |